文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Mechanism of action for Troxerutin targeting the sialylation-related gene EGLN3 for the treatment of LUAD.

作者信息

Wu Yanan, Ge Yanlei, Gan Junqing, Jin Ye, Cui Yishuang, Zheng Xuan, Yao Xuemin, Sun Guogui

机构信息

School of Public Health, North China University of Science and Technology, Tangshan, 063210, Hebei, China.

Department of Radiotherapy and Chemotherapy, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000, Hebei, China.

出版信息

Sci Rep. 2025 Mar 18;15(1):9298. doi: 10.1038/s41598-025-92028-2.


DOI:10.1038/s41598-025-92028-2
PMID:40102484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11920082/
Abstract

Studies have demonstrated that sialylation changes play a vital part in lung adenocarcinoma (LUAD), yet the specific mechanism is uncertain. Hence, in the present research, we screened sialylation-related biomarkers in LUAD using the bioinformatic strategy, predicted the drugs and performed relevant experiments to explore their role in regulating LUAD. The TCGA-LUAD, GSE31210, and GSE13213 datasets were combined to form LUAD ensemble. The sialylation-related genes (SRGs) linked with LUAD prognosis were determined by univariate Cox regression analysis, and their expressions and mutations in LUAD were analyzed in GSCA database. Then, depending on the consistent clustering of prognostic SRGs, LUAD patients were divided into sialylation-related subgroups, followed by the investigation of survival, immunity, and clinical characteristics in the subgroups. LASSO regression analysis was further employed to identify prognostic gene signatures and to build a sialylation-related model to predict the prognosis of LUAD patients. The gene signature were validated using RT-qPCR and used for predicting target medicines using molecular docking to further investigate the potential therapies for LUAD patients. A total of 26 SRGs in LUAD ensemble were associated with prognosis, and LUAD samples were classified into two sialylation-related subgroups based on these SRGs. Intergroup comparisons revealed that patients in Cluster A had greater survival rates, as well as higher immune infiltration. The risk prognostic model built based on 6 prognostic gene signature was able to effectively predict the survival of LUAD patients. Finally, the experimental findings indicated that Troxerutin exhibits a strong binding energy to the sialylation-related gene EGLN3, which could greatly reduce the growth of LUAD by inhibiting the expression of EGLN3, thus limiting the capacity of LUAD cells in the proliferation, migration, and invasion. Troxerutin could target and lower the expression of sialylation-related gene EGLN3, reducing LUAD cells' ability to proliferate, migrate, and invade, making it an essential reference for LUAD prevention and treatment.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/7c14f8c79815/41598_2025_92028_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/02dbf1e50e35/41598_2025_92028_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/fe92b069fcce/41598_2025_92028_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/865388312317/41598_2025_92028_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/abade32f263c/41598_2025_92028_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/6ccf84484a46/41598_2025_92028_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/05a79db1a1d0/41598_2025_92028_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/7c14f8c79815/41598_2025_92028_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/02dbf1e50e35/41598_2025_92028_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/fe92b069fcce/41598_2025_92028_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/865388312317/41598_2025_92028_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/abade32f263c/41598_2025_92028_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/6ccf84484a46/41598_2025_92028_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/05a79db1a1d0/41598_2025_92028_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a32c/11920082/7c14f8c79815/41598_2025_92028_Fig7_HTML.jpg

相似文献

[1]
Mechanism of action for Troxerutin targeting the sialylation-related gene EGLN3 for the treatment of LUAD.

Sci Rep. 2025-3-18

[2]
Five-gene prognostic model based on autophagy-dependent cell death for predicting prognosis in lung adenocarcinoma.

Sci Rep. 2024-11-2

[3]
The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment.

BMC Cancer. 2025-1-13

[4]
C6 and KLRG2 are pyroptosis subtype-related prognostic biomarkers and correlated with tumor-infiltrating lymphocytes in lung adenocarcinoma.

Sci Rep. 2024-10-22

[5]
The prognostic value of bioinformatics analysis of ECM receptor signaling pathways and LAMB1 identification as a promising prognostic biomarker of lung adenocarcinoma.

Medicine (Baltimore). 2024-9-20

[6]
Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma.

BMC Cancer. 2025-4-1

[7]
Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.

Aging (Albany NY). 2024-6-10

[8]
Development of a reliable risk prognostic model for lung adenocarcinoma based on the genes related to endotheliocyte senescence.

Sci Rep. 2025-4-12

[9]
A Novel Neutrophil Extracellular Trap Signature Predicts Patient Chemotherapy Resistance and Prognosis in Lung Adenocarcinoma.

Mol Biotechnol. 2025-5

[10]
FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.

Life Sci. 2021-3-1

本文引用的文献

[1]
The immune microenvironment of lung adenocarcinoma featured with ground-glass nodules.

Thorac Cancer. 2024-7

[2]
The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma.

Sci Rep. 2024-4-17

[3]
UBE2C is a diagnosis and therapeutic biomarker involved in immune infiltration of cancers including lung adenocarcinoma.

J Cancer. 2024-1-27

[4]
Identification and validation of chromatin regulator-related signatures as a novel prognostic model for low-grade gliomas using translational bioinformatics.

Life Sci. 2024-1-1

[5]
Regulation of Ferroptosis in Lung Adenocarcinoma.

Int J Mol Sci. 2023-9-27

[6]
MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy.

Int J Mol Sci. 2023-8-27

[7]
Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.

Front Immunol. 2023

[8]
A five-collagen-based risk model in lung adenocarcinoma: prognostic significance and immune landscape.

Front Oncol. 2023-7-5

[9]
Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.

Apoptosis. 2023-10

[10]
Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.

Sci Rep. 2023-4-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索